Geropsychopharmacology: Enhancing Benefit, Reducing Risk

老年精神药理学：增强效益，降低风险

• 批准号: 6463316
• 负责人: BRUCE G POLLOCK
• 金额: $ 11.76万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6463316
• 关键词: Alzheimer's disease; antidepressants; antipsychotic agents; citalopram; dementia; gene environment interaction; genetic polymorphism; geriatrics; hospital patient care; human old age (65+); human subject; human therapy evaluation; mental disorder chemotherapy; outpatient care; patient oriented research; pharmacokinetics; postdoctoral investigator; psychological tests; psychopharmacology; risperidone; serotonin inhibitor; therapy adverse effect; therapy compliance

Description (provided by applicant): Patents older than age 65 represent 13 percent of the U.S. population, yet they receive more than 35 percent of all prescription drugs and disproportionately suffer adverse experiences from psychotropic medications. The critical gaps in our knowledge of appropriate pharmacotherapy for elders with psychiatric illness are exacerbated by the shortage of new investigators trained in geriatric clinical pharmacology. This K24 award addresses this important problem by supporting further career development for an established investigator in geriatric psychopharmacology and his mentoring of junior investigators in patient-oriented research. The overarching goal of this candidate's research program is to determine inter-individual pharmacokinetic and pharmacodynamic variables affecting treatment outcome as well as to specifically address the dearth of information regarding newer antidepressants and antipsychotics in elderly patients. The primary developmental goal during the proposed K24 award period is for the candidate to enhance his expertise in population pharmacokinetics using mixed-effects modeling. This builds on the current strengths of his research program, and represents a very significant enhancement by permitting more optimal utilization of sparse drug concentration data from clinical trials. The secondary developmental goal is for the candidate to deepen his knowledge of basic and quantitative genetics. Developmental activities will occur primarily in the context of the candidate's current R01 "Continuation Pharmacotherapy for Agitation in Dementia". The goal of this study is to improve the treatment of non-cognitive symptoms of dementia in severely affected patients. This protocol will test if the highly selective serotonin reuptake inhibitor (SSRI) citalopram and the atypical antipsychotic risperidone are differentially effective in ameliorating behavioral symptoms and/or psychosis particularly during continuing pharmacotherapy upon discharge from a hospital setting. The candidate also proposes to enhance his skills as a mentor by working closely with experienced medical educators. He will recruit at least two new trainees per year through three Departmental training grants with which he is closely associated. Trainees will be medical students, residents, post-doctoral fellows and junior faculty. Particular emphasis will be given to increasing recruitment of under-represented minorities. The applicant will mentor trainees in analyses of existing data as well as design and implementation of clinical studies. Success in mentoring will be judged by trainee's productivity in peer-reviewed publications and competition for career development awards and research funding.

描述（申请人提供）：65岁以上的专利代表13 美国人口的百分比却获得了所有人的35％以上 处方药和不成比例遭受不利的经历 精神药物。我们了解适当的关键差距 患有精神病长者的药物治疗因 缺乏接受老年临床药理学培训的新研究人员。这 K24奖通过支持进一步的职业来解决这个重要问题 为老年心理药理学领域的既定研究者开发 他在以患者为导向的研究中对初级研究人员进行指导。这 该候选人研究计划的总体目标是确定 个体间的药代动力学和药效动力学变量影响 治疗结果以及专门解决信息的缺乏 关于老年患者的新抗抑郁药和抗精神病药。这 在拟议的K24颁奖期间的主要发展目标是 候选人使用 混合效应建模。这是基于他的研究的当前优势 程序，并通过允许更多来代表非常重要的增强 临床试验中稀疏药物浓度数据的最佳利用。这 次要发展目标是让候选人加深他对 基本和定量遗传学。发展活动将主要发生 在候选人目前的R01“持续药物治疗的背景下 痴呆症的躁动”。这项研究的目的是改善 严重影响患者的痴呆症的非认知症状的治疗。 该方案将测试高度选择性的5-羟色胺再摄取抑制剂 （SSRI）Citalopram和非典型抗精神病药物是差异的 有效缓解行为症状和/或精神病，特别是 在出院后继续进行药物治疗期间。 候选人还建议通过工作来提高他作为导师的技能 与经验丰富的医学教育者密切相关。他将至少招募两个新的 他每年通过三项部门培训补助 密切相关。学员将是医学生，居民，博士后 研究员和初级教师。 特别强调增加 招募代表性不足的少数民族。申请人将指导受训者 在现有数据的分析以及临床研究的设计和实施中。 在同行评审中，学员的生产力将根据学员的生产力来评判指导的成功 出版物和职业发展奖和研究的竞争 资金。